{"DataElement":{"publicId":"6692803","version":"1","preferredName":"Cytokine Release Syndrome Occurrence Cytokine Release Syndrome Grade","preferredDefinition":"A syndrome that occurs after therapeutic infusion of antibodies into the blood and is characterized by nausea, headache, tachycardia, hypotension, rash, and shortness of breath. It is caused by the release of cytokines from the cells that are targeted by the antibodies. Most patients experience a mild to moderate reaction; however, the reaction may be severe and life-threatening.","longName":"CYT_RS_GRADE","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"5118119","version":"1","preferredName":"Cytokine Release Syndrome Occurrence","preferredDefinition":"A syndrome that occurs after therapeutic infusion of antibodies into the blood and is characterized by nausea, headache, tachycardia, hypotension, rash, and shortness of breath. It is caused by the release of cytokines from the cells that are targeted by the antibodies. Most patients experience a mild to moderate reaction; however, the reaction may be severe and life-threatening._An instance of something happening, such as an event or incident.","longName":"5118117v1.0:2234856v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"5118117","version":"1","preferredName":"Cytokine Release Syndrome","preferredDefinition":"A syndrome that occurs after therapeutic infusion of antibodies into the blood and is characterized by nausea, headache, tachycardia, hypotension, rash, and shortness of breath. It is caused by the release of cytokines from the cells that are targeted by the antibodies. Most patients experience a mild to moderate reaction; however, the reaction may be severe and life-threatening.","longName":"C78251","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytokine Release Syndrome","conceptCode":"C78251","definition":"A syndrome that occurs after therapeutic infusion of antibodies into the blood and is characterized by nausea, headache, tachycardia, hypotension, rash, and shortness of breath. It is caused by the release of cytokines from the cells that are targeted by the antibodies. Most patients experience a mild to moderate reaction; however, the reaction may be severe and life-threatening.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2ACF44B8-A636-9D7E-E050-BB89AD432CA3","latestVersionIndicator":"Yes","beginDate":"2016-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-02","modifiedBy":"ONEDATA","dateModified":"2016-02-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2234856","version":"1","preferredName":"Occurrence","preferredDefinition":"Occurrence; an instance of something happening.","longName":"C25275","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Occurrence","conceptCode":"C25275","definition":"An instance of something happening, such as an event or incident.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9860F29-72B8-7421-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-14","modifiedBy":"ONEDATA","dateModified":"2005-06-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2ACF44B8-A644-9D7E-E050-BB89AD432CA3","latestVersionIndicator":"Yes","beginDate":"2016-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-02","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6692798","version":"1","preferredName":"Cytokine Release Syndrome Grade","preferredDefinition":"A syndrome that occurs after therapeutic infusion of antibodies into the blood and is characterized by nausea, headache, tachycardia, hypotension, rash, and shortness of breath. It is caused by the release of cytokines from the cells that are targeted by the antibodies. Most patients experience a mild to moderate reaction; however, the reaction may be severe and life-threatening._A position on a scale of intensity or amount or quality.","longName":"CRS_GRADE","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"4","valueDescription":"Grade 4: Life-threatening symptoms; requirement for urgent intervention, ventilator support, or Grade 4 organ toxicity (excluding transaminitis).","ValueMeaning":{"publicId":"6692799","version":"1","preferredName":"Grade 4: Life-threatening symptoms; requirement for urgent intervention, ventilator support, or Grade 4 organ toxicity (excluding transaminitis).","longName":"6692799","preferredDefinition":"Grade 4: Life-threatening symptoms; requirement for urgent intervention, ventilator support, or Grade 4 organ toxicity (excluding transaminitis).","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"869A8F27-6F8C-67D8-E053-F662850A502A","latestVersionIndicator":"Yes","beginDate":"2019-04-15","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-15","modifiedBy":"TSESU","dateModified":"2022-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"869A8F27-6FA5-67D8-E053-F662850A502A","beginDate":"2019-04-15","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-15","modifiedBy":"ONEDATA","dateModified":"2019-04-15","deletedIndicator":"No"},{"value":"3","valueDescription":"Grade 3: Symptoms require and respond to aggressive intervention; oxygen, requirement >=40%, or hypotension requiring one vasopressor, or Grade 3 organ toxicity or grade 4 transaminitis.","ValueMeaning":{"publicId":"6692800","version":"1","preferredName":"Grade 3: Symptoms require and respond to aggressive intervention; oxygen, requirement >=40%, or hypotension requiring one vasopressor, or Grade 3 organ toxicity or grade 4 transaminitis.","longName":"6692800","preferredDefinition":"Grade 3: Symptoms require and respond to aggressive intervention; oxygen, requirement >=40%, or hypotension requiring one vasopressor, or Grade 3 organ toxicity or grade 4 transaminitis.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"869A8F27-6FAF-67D8-E053-F662850A502A","latestVersionIndicator":"Yes","beginDate":"2019-04-15","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-15","modifiedBy":"TSESU","dateModified":"2022-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"869A8F27-6FC8-67D8-E053-F662850A502A","beginDate":"2019-04-15","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-15","modifiedBy":"ONEDATA","dateModified":"2019-04-15","deletedIndicator":"No"},{"value":"2","valueDescription":"Grade 2: Symptoms require and respond to moderate intervention; oxygen requirement <40%, or hypotension responsive to fluids or Grade 2 organ toxicity.","ValueMeaning":{"publicId":"6692801","version":"1","preferredName":"Grade 2: Symptoms require and respond to moderate intervention; oxygen requirement <40%, or hypotension responsive to fluids or Grade 2 organ toxicity.","longName":"6692801","preferredDefinition":"Grade 2: Symptoms require and respond to moderate intervention; oxygen requirement <40%, or hypotension responsive to fluids or Grade 2 organ toxicity.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"869A8F27-6FD2-67D8-E053-F662850A502A","latestVersionIndicator":"Yes","beginDate":"2019-04-15","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-15","modifiedBy":"TSESU","dateModified":"2022-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"869A8F27-6FEB-67D8-E053-F662850A502A","beginDate":"2019-04-15","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-15","modifiedBy":"ONEDATA","dateModified":"2019-04-15","deletedIndicator":"No"},{"value":"1","valueDescription":"Grade 1: Symptoms are not life threatening and require symptomatic treatment only (e.g., fever, nausea, fatigue, headache.","ValueMeaning":{"publicId":"6692802","version":"1","preferredName":"Grade 1: Symptoms are not life threatening and require symptomatic treatment only (e.g., fever, nausea, fatigue, headache.","longName":"6692802","preferredDefinition":"Grade 1: Symptoms are not life threatening and require symptomatic treatment only (e.g., fever, nausea, fatigue, headache.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"869A8F27-6FF5-67D8-E053-F662850A502A","latestVersionIndicator":"Yes","beginDate":"2019-04-15","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-15","modifiedBy":"TSESU","dateModified":"2022-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"869A8F27-700E-67D8-E053-F662850A502A","beginDate":"2019-04-15","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-15","modifiedBy":"ONEDATA","dateModified":"2019-04-15","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6692797","version":"1","preferredName":"Cytokine Release Syndrome Grade","preferredDefinition":"A syndrome that occurs after therapeutic infusion of antibodies into the blood and is characterized by nausea, headache, tachycardia, hypotension, rash, and shortness of breath. It is caused by the release of cytokines from the cells that are targeted by the antibodies. Most patients experience a mild to moderate reaction; however, the reaction may be severe and life-threatening.:A position on a scale of intensity or amount or quality.","longName":"C78251:C48309","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytokine Release Syndrome","conceptCode":"C78251","definition":"A syndrome that occurs after therapeutic infusion of antibodies into the blood and is characterized by nausea, headache, tachycardia, hypotension, rash, and shortness of breath. It is caused by the release of cytokines from the cells that are targeted by the antibodies. Most patients experience a mild to moderate reaction; however, the reaction may be severe and life-threatening.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Grade","conceptCode":"C48309","definition":"A position on a scale of intensity or amount or quality.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"869A8F27-6F68-67D8-E053-F662850A502A","latestVersionIndicator":"Yes","beginDate":"2019-04-15","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-15","modifiedBy":"ONEDATA","dateModified":"2019-04-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"869A8F27-6F79-67D8-E053-F662850A502A","latestVersionIndicator":"Yes","beginDate":"2019-04-15","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-15","modifiedBy":"SETRAKIN","dateModified":"2019-06-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[{"name":"CRSGRADE_RSORRES","type":"OID, AMC","context":"AMC"}],"ReferenceDocuments":[{"name":"Cytokine Release Syndrome gra","type":"Preferred Question Text","description":"Cytokine Release Syndrome grade:","url":null,"context":"COG"},{"name":"AMC CRF Text 1","type":"Alternate Question Text","description":"CRS grade","url":null,"context":"AMC"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"869A77E6-DA69-6DCC-E053-F662850A2418","latestVersionIndicator":"Yes","beginDate":"2019-04-15","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-15","modifiedBy":"TSESU","dateModified":"2023-03-22","changeDescription":"System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}